OQROStart free trial
Insider trade

Johnson & Johnson (JNJ): CEO sold ~$22.5M

Joaquin Duato, CEO at Johnson & Johnson, sold ~$22.5M of Johnson & Johnson shares.

~$22.5M
Approx. value · 126K sh @ $179.21
276K
Holds after · shares reported
Traded
Aug 22, 2025
Filed
Aug 25, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 15, 2023CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Aug 7, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  3. Sep 26, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  4. Oct 29, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  5. Mar 19, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  6. Jun 10, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  7. Jun 16, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  8. Jun 17, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  9. Jun 24, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  10. Jul 17, 2025InsiderOfficer sold ~$3.13M of JNJ shares in the open market
  11. Jul 31, 2025CongressDisclosed partial sale of JNJ — reported range $15,001 - $50,000
  12. Aug 4, 2025Congress · 1 personMembers of Congress: 2 purchases
  13. Aug 14, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  14. Aug 15, 2025InsiderCFO sold ~$2.98M of JNJ shares in the open market
  15. Aug 19, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  16. Aug 22, 2025 · this disclosureInsiderCEO sold ~$22.5M of JNJ shares in the open market

What came next

  1. Sep 4, 2025Insider · 4 days before an 8-KOfficer sold ~$10M of JNJ shares in the open market
  2. Sep 8, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 8, 2025, Johnson & Johnson (the Company) announced that John Morikis was elected to the Board of Directors. The Board has determined that Mr. Morikis satisfies the applicable independence requirements of the NYSE Listed Company Manual.”
  3. Sep 23, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  4. Sep 26, 2025FDAFDA drug approval: Tremfya
  5. Oct 1, 2025FDARecall: Automated Impella Controller (AIC), used for left heart support blood pump, labeled as the following with corresponding Product Codes: 1. Impella Controller, P…
  6. Oct 8, 2025FDAFDA device clearance: 14Fr Low Profile Introducer Kit
  7. Oct 9, 2025Federal contract · $19K obligatedDepartment of Veterans Affairs awarded Johnson & Johnson: $19K obligated to date
  8. Oct 10, 2025Congress · 1 personMembers of Congress: 2 sales
  9. Oct 14, 2025Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  10. Oct 16, 2025Federal contract · $384K obligatedDepartment of Defense awarded Johnson & Johnson: $384K obligated to date
  11. Oct 17, 2025InsiderOfficer sold ~$4.19M of JNJ shares in the open market
  12. Oct 18, 2025FDARecall: MONARCH Bronchoscope. Model Number: MBR-000211-B
  13. Oct 21, 2025FDAFDA device clearance: TriALTIS™ Spine System
  14. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  15. Oct 31, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  16. Nov 5, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  17. Nov 6, 2025FDAFDA drug approval: Darzalex Faspro
  18. Nov 12, 2025FDAFDA device clearance: Synthes Patient Specific Implants
  19. Nov 12, 2025FDAFDA device clearance: PDS™ Plus Antibacterial (Polydioxanone) Sterile Synthetic Absorbable Surgical Suture
  20. Nov 13, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 14 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 119 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

Other recent filings by Joaquin Duato, CEO and Chairman of the Board

The full history of Joaquin Duato, CEO and Chairman of the Board is on the profile page.

How this filing works

Explore the data

Other disclosures at Johnson & Johnson

Everything OQRO holds on this company is on its JNJ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Start free trialAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data